Trials / Completed
CompletedNCT04538599
RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- He Huang · Academic / Other
- Sex
- All
- Age
- 3 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to explore the safety of RD13-01 for patients with CD7+ relapsed and/or refractory T/NK-cell hematologic malignancies. And to evaluate the efficacy and pharmacokinetics of RD13-01 in patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RD13-01 cell infusion | Universal CAR-T cells targeting CD7 |
Timeline
- Start date
- 2020-09-10
- Primary completion
- 2021-02-17
- Completion
- 2021-11-30
- First posted
- 2020-09-04
- Last updated
- 2022-01-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04538599. Inclusion in this directory is not an endorsement.